|
Autor/a:
|
Jové Font, Mariona; Mauri-Capdevila, Gerard; Suárez-Luis, Idalmis; Cambray Carner, Serafí; Sanahuja Montesinos, Jordi; Quilez Martínez, Alejandro; Farré, Joan; Benabdelhak Abbou, Ikram; Pamplona Gras, Reinald; Portero Otín, Manuel; Purroy Garcia, Francisco
|
|
Notas:
|
Objective: To discover, by using metabolomics, novel candidate biomarkers for stroke recurrence
(SR) with a higher prediction power than present ones.
Methods: Metabolomic analysis was performed by liquid chromatography coupled to mass spectrometry
in plasma samples from an initial cohort of 131 TIA patients recruited ,24 hours after
the onset of symptoms. Pattern analysis and metabolomic profiling, performed by multivariate
statistics, disclosed specific SR and large-artery atherosclerosis (LAA) biomarkers. The use of
these methods in an independent cohort (162 subjects) confirmed the results obtained in the first
cohort.
Results: Metabolomics analyses could predict SR using pattern recognition methods. Low concentrations
of a specific lysophosphatidylcholine (LysoPC[16:0]) were significantly associated with
SR. Moreover, LysoPC(20:4) also arose as a potential SR biomarker, increasing the prediction
power of age, blood pressure, clinical features, duration of symptoms, and diabetes scale
(ABCD2) and LAA. Individuals who present early (,3 months) recurrence have a specific metabolomic
pattern, differing from non-SR and late SR subjects. Finally, a potential LAA biomarker,
LysoPC(22:6), was also described.
Conclusions: The use of metabolomics in SR biomarker research improves the predictive power of
conventional predictors such as ABCD2 and LAA. Moreover, pattern recognition methods allow us
to discriminate not only SR patients but also early and late SR cases.
Supported by the Autonomous Government of Catalunya (2009SGR- 735), the Spanish Ministry of Health (FIS 11-02033), and the Marató of TV3 Foundation (95/C/2011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Samples were obtained with the support of IRBLleida biobank and RETICS BIOBANCOS (RD09/0076/00059) |
